Announcement • Jun 17
Aptahem Improves Quality And Manufacturing Efficiency In A New Apta-1 Test Batch Aptahem announced that Hongene Biotech has successfully produced a test-batch of Aptahem's lead drug candidate, Apta-1, using a new conjugation method. The result demonstrates very high product quality, with a measured purity of approximately 99%, while the method also delivered improved manufacturing efficiency. This test-batch, which represents a first step toward further optimizing quality and lowering production costs, is a very encouraging result. Improved process efficiency, scalability and the potential for lower production costs are important factors both for upcoming regulatory processes and for future commercial success. More broadly, the result strengthens the manufacturing and quality foundation for Apta-1, which is important for future clinical development, regulatory interactions and commercial-scale production. Through more efficient production and better resource utilization, the new method is also expected to contribute to a lower cost of goods sold (CoGs), which could become an important driver of future market introduction, pricing flexibility and long-term competitiveness. For potential partners, well-established relationships with experienced pharmaceutical manufacturers are themselves an important evaluation criterion, alongside more standardized criteria such as manufacturability and cost efficiency. With these elements now demonstrably in place for Apta-1, the candidate's position in future partnering and licensing discussions is strengthened. In April 2025, Aptahem announced that the Company had entered into a strategic collaboration with Hongene Biotech, a global company within oligonucleotide chemistry and a specialized CDMO (Contract Development and Manufacturing Organisation) with one of the world's largest production capacities for oligonucleotide synthesis. Aptamers such as Apta-1 are synthetic oligonucleotides. Hongene supports the development of oligonucleotides from research-scale synthesis to commercial production. The collaboration was established with the aim of reducing manufacturing costs and improving the sustainability of Apta-1, which the results show that the Company has now achieved. Hongene Biotech operates internationally, with offices in the United States, Germany, Japan and China. Reported Earnings • May 29
First quarter 2026 earnings released: kr0.066 loss per share (vs kr0.17 loss in 1Q 2025) First quarter 2026 results: kr0.066 loss per share (improved from kr0.17 loss in 1Q 2025). Net loss: kr1.39m (loss narrowed 31% from 1Q 2025). Announcement • Apr 29
Aptahem AB (publ) to Report Q1, 2026 Results on May 28, 2026 Aptahem AB (publ) announced that they will report Q1, 2026 results on May 28, 2026 
